Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of Ilaprazole and NSAIDs in Healthy Adults
NCT05237297Phase 1Completed
- Sponsor
- Il-Yang Pharmaceutical
- Start
- Feb 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ilaprazole in peptic ulcer disease (PUD), sponsored by Il-Yang Pharmaceutical. Primary endpoints: Pharmacokinetic Parameters Part 1 (Ilaprazole Monotherapy) at 12 hours, Pharmacokinetic Parameters Part 2 (NSAID Monotherapy) at 12 hours and 1 more. Started Feb 2022; status: completed.
02
Drugs
ilaprazole
03
Conditions
peptic ulcer disease (PUD)
Beyond the preview
Go deeper on NCT05237297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05237297.